Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048165 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 434
- Enrollment target
NCT00048165 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 434 participants.
The verdict
NCT00048165, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 434 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation.
Interventions
- DRUG Placebo
- DRUG Methylprednisolone
- DRUG Mycophenolate mofetil
- DRUG cyclosporine
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 1999-08 |
| Est. Completion | 2002-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048165
The ClinicalTrials.gov registry entry for NCT00048165 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 434 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00048165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048165 about?
NCT00048165 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation". The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation.
What is the current status of trial NCT00048165?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 434 participants. The study started on 1999-08. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00048165?
The interventions under investigation include: Placebo (DRUG), Methylprednisolone (DRUG), Mycophenolate mofetil (DRUG), cyclosporine (DRUG), Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00048165?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.